Just looking at this fund, I don't think much. After all, it is a new fund, with no reference to past performance, poor assurance and great uncertainty. But judging from the current situation, I don't recommend this one for the following reasons.

In recent years, many excellent fund managers of UBS SDIC have changed their jobs. For a medium-sized fund company, the loss of three managers is no small matter, which seriously affected the performance of the previous year.

The proposed fund manager is experienced, but his past performance is not bright, that is, the average level, but UBS SDIC can also handle him, and all the better ones are looking for another job. The other is young and inexperienced, and his performance in just one year is below the average.

This is a hybrid fund, and the position is grasped. The requirements for fund managers are higher, so we must find a good manager.

There is no problem in the pharmaceutical industry, but there are already many funds in this industry on the market. Since we are optimistic about this industry, we should choose those that have been in operation for a period of time, and we are more sure to recommend Rongtong Medical and Huitianfu Medicine. The past performance fully proves that these two are excellent.

If you don't understand, sincerely welcome questions; If I am lucky enough to help you, please adopt in time! thank you